FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis

  1. 1. FluBlok (Seasonal Influenza Vaccines) Forecast and MarketAnalysisReport Details:Published:November 2012No. of Pages: 68Price: Single User License – US$6995FluBlok (Seasonal Influenza Vaccines) Forecast and Market AnalysisSummaryGlobalData has released its new PharmaPoint Drug Evaluation report, FluBlok (SeasonalInfluenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infectioncaused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough.The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection.Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip,GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of themarket. However, with the entrance of vaccines with novel routes of administration, such asAstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects adramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines.GlobalData also anticipates that manufacturers that launch quadrivalent formulations will stealmarket share, patient share, and revenue from the trivalent influenza vaccines currently available.FluBlok is being developed by the Protein Sciences Corporation (PSC), headquartered in Meriden,Connecticut in the US. FluBlok is the leading vaccine candidate in PSC’s vaccine portfolio thatalso focuses on pandemic influenza, SARS and flu vaccine adjuvants. The trivalent vaccineconsists of recombinant hemagglutinin protein, from H1, H3 and B strains, that are propagated in abaculovirus expression vector system in insect cells (FDA Briefing document). The vaccine is afirst-in-class product that is the first vaccine to use an insect cell-based manufacturing system inthe US.Scope- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis,pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on FluBlok including product description, safety and efficacy profiles as wellas a SWOT analysis.
  2. 2. - Sales forecast for FluBlok in the US from 2011 to 2022.Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape forseasonal Influenza.- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of FluBlokperformance- Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK,Italy, Spain, Japan and Australia)Get your copy of this report @http://www.reportsnreports.com/reports/213203-flublok-seasonal-influenza-vaccines-forecast-and-market-analysis.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 41.1 List of Tables 51.2 List of Figures 52 Introduction 62.1 Catalyst 62.2 Related Reports 73 Disease Overview 93.1 Etiology and Pathophysiology 93.1.1 Etiology 93.1.2 Pathophysiology 133.2 Symptoms 143.3 Prognosis 144 Disease Management 154.1 Influenza Vaccination Policy 155 Competitive Assessment 175.1 Overview 175.2 Strategic Competitor Assessment 176 Opportunity and Unmet Need 206.1 Overview 206.2 Unmet Needs 216.2.1 Higher level of patient awareness 216.2.2 Increased efficacy in the elderly and young children (6.2.3 Improved vaccine side-effectprofiles 22
  3. 3. 6.2.4 More efficient vaccine manufacturing process 226.2.5 More cost-effective vaccines 236.3 Gap Analysis 246.4 Opportunities 256.4.1 Expanded breadth of protection against viral strains 256.4.2 Increased duration of protection 266.4.3 T-cell involvement 267 Pipeline Assessment 277.1 Overview 277.2 Promising vaccines in clinical development 287.2.1 FluBlok 308 Appendix 388.1 Bibliography 388.2 Abbreviations 578.3 Methodology 598.4 Forecasting Methodology 598.4.1 Vaccine Coverage 608.4.2 Vaccines Included 608.4.3 Key Launch Dates 618.4.4 Influenza Vaccine Tender System Assumptions 628.4.5 General Pricing Assumptions 628.4.6 Pricing of Pipeline Agents 638.5 Physicians and Specialists Included in this Study 638.6 Primary Research - Prescriber Survey 648.7 About the Authors 658.7.1 Authors 658.7.2 Epidemiologists 668.7.3 Global Head of Healthcare 678.8 About GlobalData 688.9 Contact Us 688.10 Disclaimer 681.1 List of TablesTable 1: Notable Influenza Pandemics 13Table 2: Symptoms of Influenza 14Table 3: Influenza Vaccination Recommendation Committees by Country 15Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012 16Table 5: Leading Influenza Vaccines, 2012 19Table 6: Overall Unmet Needs - Current Level of Attainment 20Table 7: Clinical Unmet Needs - Gap Analysis, 2012 24Table 8: Seasonal Influenza Vaccines - Phase Pipeline, 2012 28Table 9: Product Profile - FluBlok 31
  4. 4. Table 10: FluBlok SWOT Analysis, 2012 36Table 11: Global Sales Forecasts ($m) for FluBlok, 2012-2022 37Table 12: Key Launch Dates 61Table 13: Physicians Surveyed, By Country 641.2 List of FiguresFigure 1: Influenza Virus Structure 9Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022 29Contact: sales@reportsandreports.com for more information.